Adjuvant therapy of gastrointestinal stromal tumors

Current Opinion in Oncology

Volumn 24, Issue 4, 2012, Pages 414-418

  Koshenkov, Vadim P ^a   Rodgers, Steven E ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

adjuvant; dose; gastrointestinal stromal tumors; imatinib

Indexed keywords

IMATINIB; MASITINIB; NILOTINIB; PLACEBO; SORAFENIB; SUNITINIB; VATALANIB;

ADJUVANT CHEMOTHERAPY; DRUG EFFICACY; DRUG MEGADOSE; EXON; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; HIGH RISK PATIENT; HUMAN; METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; RELAPSE; REVIEW; TREATMENT DURATION;

CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; INDOLES; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; PYRROLES;

EID: 84862147870     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0b013e328353d774     Document Type: Review

References (38)

1. Miettinen M, Lasota J. Gastrointestinal stromal tumors. Arch Pathol Lab Med 2006; 130:1466-1478.
2. Pandurengan RK, Dumon AG, Araujo DM, et al. Survival of patients with multiple primary malignancies: a study of 783 patients with gastrointestinal stromal tumor. Ann Oncol 2010; 21:2107-2111.
3. Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001; 344:1052-1056. (Pubitemid 32267975)
4. DeMatteo RP, Gold JS, Saran L, et al. Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal tumor (GIST). Cancer 2008; 112:608-615. (Pubitemid 351186201)
5. Hohenberger P, Ronellenfitsch U, Oladeji O, et al. Pattern of recurrence in patients with ruptured primary gastrointestinal stromal tumour. Br J Surg 2010; 97:1854-1859.
6. Rutkowski P, Bylina E, Wozniak A, et al. Validation of the Joensuu risk criteria for primary resectable gastrointestinal stromal tumour-the impact of tumour rupture on patient outcomes. Eur J Surg Oncol 2011; 37:890-896.
7. Corless CL, Ballman KV, Antonescu C, et al. Relation of tumor pathologic and molecular features to outcome after surgical resection of localized primary gastrointestinal stromal tumor (GIST): results of the intergroup phase III trial ACOSOG Z9001. J Clin Oncol 2010; 28 (15 Suppl.):abstr.10006.
8. Ylipaa A, Hunt KK, Yang J, et al. Integrative genomic characterization and a genomic staging system for gastrointestinal stromal tumors. Cancer 2011; 117:380-389.
9. Lagarde P, Perot G, Kauffmann A, et al. Mitotic checkpoints and chromosome instability are strong predictors of clinical outcome in gastrointestinal stromal tumors. Clin Cancer Res 2012; 18:826-838.
10. DeMatteo RP, Ballman KV, Antonescu CR, et al. Adjuvant imatinib mesylate after resection of localized, primary gastrointestinal stromal tumour: a randomized, double-blind, placebo-controlled trial. Lancet 2009; 373:1097-1104.
11. Gastrointestinal Stromal Tumor Meta-Analysis Group. Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1640 patients. J Clin Oncol 2010; 28:1247-1253.
12. Demetri GD, Wang Y, Wehrle E, et al. Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors. J Clin Oncol 2009; 27:3141-3147.
13. Yoo C, Ryu M, Kang BW, et al. Cross-sectional study of imatinib plasma trough levels in patients with advanced gastrointestinal stromal tumors: impact of gastrointestinal resection on exposure to imatinib. J Clin Oncol 2010; 28:1554-1559.
14. Joensuu H, Eriksson M, Hatrmann J, et al. Twelve versus 36 months of adjuvant imatinib (IM) as treatment of operable GIST with a high risk of recurrence: final results of a randomized trial (SSGXVII/AIO). J Clin Oncol 2011; 29(18 Suppl.):abstr. LBA1.
15. Li J, Gong JF, Wu AW, Shen L. Postoperative imatinib in patients with intermediate or high risk gastrointestinal stromal tumor. Eur J Surg Oncol 2011; 37:319-324.
16. Jiang WZ, Guan GX, Lu HS, et al. Adjuvant imatinib treatment after R0 resection for patients with high-risk gastrointestinal stromal tumors: a median follow-up of 44 months. J Surg Oncol 2011; 104:760-764.
17. McAuliffe JC, Hunt KK, Lazar AJ, et al. A randomized, phase II study of preoperative plus postoperative imatinib in GIST: evidence of rapid radiographic response and temporal induction of tumor cell apoptosis. Ann Surg Oncol 2009; 16:910-919.
18. Eisenberg BL, Harris J, Blanke CD, et al. Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665. J Surg Oncol 2009; 99:42-47.
19. Von Mehren M, Heinrich MC, Joensuu H, et al. Follow-up results after 9 years (yrs) of the ongoing, phase II B2222 trial of imatinib mesylate (IM) in patients (pts) with metastatic or unresectable KIT + gastrointestinal stromal tumors (GIST). in J Clin Oncol 2011; 29 (15 Suppl.):abstr. 10016.
20. Blesius A, Cassier PA, Ray-Coquard IL, et al. Who are the long responders to imatinib (IM) in patients with advanced GIST? Results of the BFR14 prospective French Sarcoma Group randomized phase III trial. J Clin Oncol 2011; 29 (15 Suppl.):abstr. 10048.
21. Le Cesne A, Ray-Coquard I, Bui BN, et al. Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomized phase 3 trial. Lancet Oncol 2010; 11:942-949.
22. Ray-Coquard I, Bui BN, Adenis A, et al. Risk of relapse with imatinib (IM) discontinuation at 5 years in advanced GIST patients: results of the prospective BFR14 randomized phase III study comparing interruption versus continuation of IM at 5 years of treatment: a French Sarcoma Group Study. J Clin Oncol 2010; 28 (16 Suppl.):abstr. 10032.
23. Le Cesne A, Ray-Coquard IL, Bui BN, et al. Time to secondary resistance (TSR) after interruption of imatinib (IM) in advanced GIST: updated results of the prospective French Sarcoma Group randomized phase III trial on longterm survival. J Clin Oncol 2011; 29 (15 Suppl.):abstr. 10015.
24. Wang D, Zhang Q, Blanke CD, et al. Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): long-term follow-up results of RTOG 0132. J Clin Oncol 2011; 29 (15 Suppl.):abstr. 10057.
25. Demetri G, Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomized controlled trial. Lancet 2006; 368:1329-1338. (Pubitemid 44528723)
26. Le Cesne A, Blay JY, Bui BN, et al. Phase II study of oral masitinib mesylate in imatinib-na?̈ve patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST). Eur J Cancer 2010; 46:1344-1351.
27. Blay J, Le Cesne A, Bui BN, et al. Overall survival benefit with masitinib mesylate in imatinib-na?̈ve, locally advanced, or metastatic gastrointestinal stromal tumor (GIST): 4-years follow-up of the French Sarcoma Group phase II trial. J Clin Oncol 2011; 29 (4 Suppl.):abstr. 85.
28. Efficacy and safety of masitinib (AB1010) in comparison to imatinib in patients with gastro-intestinal stromal tumour. Available at http://clinicaltrials.gov/show/NCT00812240. [Accessed March 10 2012].
29. Nishida T, Sawaki A, Doi T, et al. Phase II trial of nilotinib as third-line therapy for gastrointestinal stromal tumor (GIST) patients in Japan. J ClinOncol 2010; 28 (15 Suppl.):abstr. 10015.
30. Reichardt P, Blay J, Gelderblom H, et al. Phase III trial of nilotinib in patients with advanced gastrointestinal stromal tumor (GIST): first results from ENEST g3. J Clin Oncol 2010; 28(15 Suppl.):abstr. 10017.
31. Joensuu H, De Braud F, Grignagni G, et al. Vatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: final results of a phase II study. Br J Cancer 2011; 104:1686-1690.
32. Kindler HL, Campbell NP, Wroblewski K, et al. Sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): final results of a University of Chicago phase II consortium trial. J Clin Oncol 2011; 29 (15 Suppl.):abstr. 10009.
33. Blesius A, Cassier PA, Bertucci F, et al. Neoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BFR14 trial. BMC Cancer 2011; 11:72-78.
34. Duffaud F, Cassier PA, Adenis A, et al. Gastrointestinal stromal tumor (GIST) of the rectum and pararectal space: a French Sarcoma Group (FSG) retrospective review. J Clin Oncol 2010; 28 (15 Suppl.):abstr. 10055.
35. Sjolund K, Andersson A, Nilsson E, et al. Downsizing treatment with tyrosine kinase inhibitors in patients with advanced gastrointestinal stromal tumors improved respectability. World J Surg 2010; 34:2090-2097.
36. Mussi C, Ronellenfitsch U, Jakob J, et al. Postimatinib surgery in advanced/metastaticGIST: is it worthwhile in all patients? AnnOncol2010; 21:403-408.
37. Yeh CN, Chen TW, Tseng JH, et al. Surgical management in metastatic gastrointestinal stromal tumor (GIST) patients after imatinib mesylate treatment. J Surg Oncol 2010; 102:599-603.
38. Raut CP, Wang Q, Manola J, et al. Cytoreductive surgery in patients with metastatic gastrointestinal stromal tumor treated with sunitinib malate. Ann Surg Oncol 2010; 17:407-415.